Back to results
US 11,692,024 B2Granted
Methods of treating AL amyloidosis
AssigneeProthena Biosciences Limited
InventorsGene Kinney, Carol Karp, Wagner Marcelo Zago, Radhika Tripuraneni
Life of this patent
Estimating the term…
Abstract
Antibody formulations and methods useful for treatment of patients with AL amyloidosis.
Claims42
A method of treating a patient having AL amyloidosis, comprising:
- (a) determining:
- (i) the Mayo Stage of the patient's AL amyloidosis;
- (ii) the 6 minute walk distance (6MWD) and ejection fraction (EF) of the patient;
- (iii) the Mayo Stage of the patient's AL amyloidosis and the EF of the patient;
- or
- (iv) the Mayo Stage of the patient's AL amyloidosis, and the 6MWD and the EF of the patient;
- and
- (b) selecting the patient for treatment with an antibody comprising a light chain variable region comprising three complementarity determining regions set forth as SEQ ID NOs:
- 3, 4 and 5, and a heavy chain variable region comprising three complementarity determining regions set forth as SEQ ID NOs:
- 6, 7 and 8 if the patient:
- (i) has Mayo Stage IV AL amyloidosis;
- (ii) has a 6MWD≥150 meters and an EF>50% at baseline;
- (iii) has Mayo Stage IV AL amyloidosis and EF>50% at baseline;
- or
- (iv) has Mayo Stage IV AL amyloidosis, a 6MWD≥150 meters and an EF>50% at baseline;
- and
- (c) administering an effective dosage of the antibody to the selected patient.
14 more elements
A method of treating a patient having AL amyloidosis, comprising:
- (a) selecting a patient having AL amyloidosis for treatment with an antibody comprising a light chain variable region comprising three complementarity determining regions set forth as SEQ ID NOs:
- 3, 4 and 5, and a heavy chain variable region comprising three complementarity determining regions set forth as SEQ ID NOs:
- 6, 7 and 8 if the patient has:
- (i) Mayo Stage IV AL amyloidosis;
- (ii) a 6 minute walk distance (6MWD)≥150 meters and EF>50% at baseline;
- (iii) Mayo Stage IV AL amyloidosis and an EF>50% at baseline;
- or
- (iv) Mayo Stage IV AL amyloidosis and a 6MWD≥150 meters and EF>50% at baseline;
- and
- (b) administering an effective dosage of the antibody to the selected patient.
7 more elements
A method of treating a patient with AL amyloidosis, comprising:
- (a) selecting a patient with AL amyloidosis having a 6 minute walk distance (6MWD)≥150 meters and an ejection fraction (EF)>50% at baseline for treatment with an antibody comprising a light chain variable region comprising three complementarity determining regions set forth as SEQ ID NOs:
- 3, 4 and 5, and a heavy chain variable region comprising three complementarity determining regions set forth as SEQ ID NOs:
- 6, 7 and 8;
- and
- (b) administering an effective dosage of the antibody to the selected patient.
2 more elements
A method of treating a patient with AL amyloidosis comprising:
- (a) selecting a patient having AL amyloidosis for treatment with an antibody comprising a light chain variable region comprising three complementarity determining regions set forth as SEQ ID NOs:
- 3, 4 and 5, and a heavy chain variable region comprising three complementarity determining regions set forth as SEQ ID NOs:
- 6, 7 and 8, if the patient has Mayo Stage IV AL amyloidosis, a 6 minute walk distance (6MWD)≥150 meters, and an ejection fraction (EF)>50% at baseline;
- and
- (b) administering an effective dosage of the antibody to the selected patient.
2 more elements
A method of reducing the risk of mortality in a patient with AL amyloidosis by at least 45%, comprising:
- (a) selecting a patient having AL amyloidosis for treatment with an antibody comprising a light chain variable region comprising three complementarity determining regions set forth as SEQ ID NOs:
- 3, 4 and 5, and a heavy chain variable region comprising three complementarity determining regions set forth as SEQ ID NOs:
- 6, 7 and 8 if the patient has:
- (i) Mayo Stage IV AL amyloidosis;
- (ii) a 6MWD of greater than or equal to 150 meters and an EF of more than 50% at baseline, or
- (iii) Mayo Stage IV AL amyloidosis and an EF of >50% at baseline;
- and
- (b) administering an effective dosage of the antibody to the selected patient.
5 more elements
A method of improving a 6 minute walk distance (6MWD) in a patient having AL amyloidosis, comprising:
- (a) selecting a patient having AL amyloidosis for treatment with an antibody comprising a light chain variable region comprising three complementarity determining regions set forth as SEQ ID NOs:
- 3, 4 and 5, and a heavy chain variable region comprising three complementarity determining regions set forth as SEQ ID NOs:
- 6, 7 and 8 if the patient has a 6MWD≥150 meters and EF>50% at baseline, and
- (b) administering an effective dosage of the antibody to the selected patient.
1 more element
Dependencies are inferred from the claim text.